Skip to Content

GN’s Proposed Capital Raise Withdrawn From Annual General Meeting; Shares Undervalued

""

GN Store Nord GN, which previously announced its intent to increase share capital through a pre-emptive rights issue to existing shareholders for as much as DKK 7 billion in February, held its annual general meeting on March 15. The board of directors’ proposal for the rights issue was withdrawn as advance votes and shareholder response voiced opposition. GN did comment that roughly half of the received votes were for the rights issue, but the proposal required a two-thirds majority to be passed, and so it was removed from the meeting agenda.

Without the rights issue, and with around DKK 7 billion of debt coming due in 2024, GN’s board is in a tougher spot to balance paying down debt to achieve the goal of 1-2.0 times net interest-bearing debt/EBITDA with having cash on hand to fund growth. However, GN does have a revolving credit facility of EUR 350 million (approximately DKK 2.6 billion at current exchange rates). Provided it does not pay dividends or complete additional share buybacks and is prudent with capital expenditures over fiscal 2023 and 2024, we believe GN will be able to meet its debt requirements without a rights issuance but by utilizing the revolving credit facility as necessary.

Additionally, GN built up inventory between fiscal 2020 and 2022 in response to first the coronavirus pandemic and then global supply chain issues. We anticipate that it will work to decrease its held inventory and increase days payable outstanding to more normalized historical levels during 2023, freeing up additional cash. It would take longer to reduce GN’s net interest-bearing debt/EBITDA ratio from 7.1 at the end of fiscal 2022 to the board’s goal of 1-2.0 than via the capital raise, but it would not have the same value-destructive effect as a DKK 7 billion rights issuance.

We are updating our model to incorporate these additional factors and the weaker markets seen in fiscal 2022 but view the shares as undervalued at current prices.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Alex Morozov

Regional Director
More from Author

Alex Morozov, CFA, is director of European equity research for Morningstar Holland BV, a wholly owned subsidiary of Morningstar, Inc. He leads a team of equity analysts based in Europe who cover European and global companies across all major sectors of the economy.

Before assuming his current role in 2014, Morozov was head of global healthcare equity research. Previously, he was a senior equity analyst, covering the medical instruments, life sciences, and diagnostics industries. Before joining Morningstar in 2006, Morozov worked in the insurance industry.

Morozov holds a bachelor’s degree in finance, with a minor in mathematics, from the University of Missouri. He also holds the Chartered Financial Analyst® designation.

Sponsor Center